Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 285-294

  Adema, A D ^a   Laan, A C ^a   Myhren, F ^b   Fichtner, I ^c   Verheul, H M ^a   Sandvold, M L ^b   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Clavis Pharma ASA   (Norway)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Cell cycle; CP 4055; CP 4126; Cytarabine; Docetaxel; Fatty acid; Gemcitabine; Oxaliplatin

Indexed keywords

CP 4055; CP 4126; CYTARABINE DERIVATIVE; DOCETAXEL; ELACYTARABINE; FATTY ACID DERIVATIVE; GEMCITABINE; OXALIPLATIN; PEMETREXED; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; EVENING DOSAGE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MORNING DOSAGE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CYTARABINE; DEOXYCYTIDINE; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY ACIDS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; TAXOIDS;

EID: 74549123857     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000499     Document Type: Article

References (44)

1. Hubeek I, Kaspers GJ, Ossenkoppele GJ and Peters GJ: Cytosine arabinoside: metabolism, mechanism of resistance, and clinical pharmacology. In: Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy. Peters GJ (ed). Humana Press Inc., Totowa, pp119-152, 2006.
2. Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33, 2002.
3. Plunkett W, Huang P, Searcy CE and Gandhi V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3-15, 1996.
4. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
5. Plunkett W and Gandhi V: Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20: 50-63, 1993.
6. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998.
7. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J and Casado FJ: Cell entry and export of nucleoside analogues. Virus Res 107: 151-164, 2005.
8. Breistol K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq E and Fodstad O: Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 59: 2944-2949, 1999.
9. Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR and Peters GJ: Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 67: 503-511, 2004.
10. Bergman AM, Kuiper CM, Myhren F, Sandvold ML, Hendriks HR and Peters GJ: Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 23: 1523-1526, 2004.
11. Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Fodstad O, Breistol K and Peters GJ: Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides Nucleotides Nucleic Acids 23: 1329-1333, 2004.
12. Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM and Rasch W: Intravenous administration of CP-4055 (ELACY™) in patients with solid tumours. A phase I study. Acta Oncol 48: 137-145, 2008.
13. Adams DJ, Sandvold ML, Myhren F, Jacobsen TF, Giles F and Rizzieri DA: Anti proliferative activity of ELACYT (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 49: 786-797, 2008.
14. Faivre S, Chan D, Salinas R, Woynarowska B and Woynarowski JM: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66: 225-237, 2003.
15. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
16. Ramalingam S and Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 (Suppl 1): S5-S13, 2008.
17. Bergman AM, Ruiz van Haperen V, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530, 1996.
18. Braakhuis BJ, Ruiz van Haperen V, Welters MJ and Peters GJ: Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A: 2335-2340, 1995.
19. Fruh M, Gillessen S, Cerny T, Demmer R and D'Addario G: Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer 62: 344-350, 2008.
20. Kakolyris S, Ziras N, Vamvakas L, Varthalitis J, Papakotoulas P, Syrigos K, Vardakis N, Kalykaki A, Amarantidis K and Georgoulias V: Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced nonsmall cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 54: 347-352, 2006.
21. Cappuzzo F, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, Lorusso V, Barbieri F, Castaldini L, Crucitta E, Marini L, Bartolini S, Scagliotti GV and Crino L: Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 93: 29-34, 2005.
22. Bidoli P, Stani SC, Mariani L, De Candis D, Cortinovis D, Aglione S, Zilembo N, Toffolatti L, Formisano B and Bajetta E: Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer 43: 203-208, 2004.
23. Jordan MA and Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130, 1998.
24. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997.
25. Belani CP: Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer 50 (Suppl. 2): S3-S8, 2005.
26. Gibbs D and Jackman A: Pemetrexed disodium. Nat Rev Drug Discov (Suppl): S16-S17, 2005.
27. Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L and Mavroudis D: Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 59: 57-63, 2008.
28. Nagai S, Takenaka K, Sonobe M, Wada H and Tanaka F: Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. Chemotherapy 54: 166-175, 2008.
29. Beausejour CM, Gagnon J, Primeau M and Momparler RL: Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 293: 1478-1484, 2002.
30. Backus HH, Pinedo HM, Wouters D, Padron JM, Molders N, van der Wilt CL, van Groeningen CJ, Jansen G and Peters GJ: Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 87: 771-778, 2000.
31. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B and Pinedo HM: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900, 1991.
32. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
33. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM and Ackland SP: Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253, 2000.
34. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
35. Temmink OH, de Bruin M, Comijn EM, Fukushima M and Peters GJ: Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs 16: 285-292, 2005.
36. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ and Peters GJ: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80: 981-990, 1999.
37. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T and Bibby M: Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40: 298-307, 2004.
38. Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ and Pinedo HM, Peters GJ: Sequence-dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 83: 1069-76, 2000.
39. van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE and Peters GJ: Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35: 808-814, 1999.
40. Zupi G, Scarsella M, D'Angelo C, Biroccio A, Paoletti G, Lopez M and Leonetti C: Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther 4: 866-871, 2005.
41. Tolis C, Peters GJ, Ferreira CG, Pinedo HM and Giaccone G: Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35: 796-807, 1999.
42. Sampath D, Rao VA and Plunkett W: Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22: 9063-9074, 2003.
43. Andreassen PR, Lacroix FB, Lohez OD and Margolis RL: Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res 61: 7660-7668, 2001.
44. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M and Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68: 110-118, 2005.